Additional file 1 of Multi-scale pathology image texture signature is a prognostic factor for resectable lung adenocarcinoma: a multi-center, retrospective study
Creators: name: Wang, Yumeng
name: Pan, Xipeng
name: Lin, Huan
name: Han, Chu
name: An, Yajun
name: Qiu, Bingjiang
name: Feng, Zhengyun
name: Huang, Xiaomei
name: Xu, Zeyan
name: Shi, Zhenwei
name: Chen, Xin
name: Li, Bingbing
name: Yan, Lixu
name: Lu, Cheng
name: Li, Zhenhui
name: Cui, Yanfen
name: Liu, Zaiyi
name: Liu, Zhenbing
Publisher: name: figshare
Year: 2024
Subjects: subject: Biochemistry
subject: Medicine
subject: Cell Biology
subject: Genetics
subject: FOS: Biological sciences
subject: Mathematical Sciences not elsewhere classified
subject: Cancer

description: Additional file 1: Section 1. Inclusion and exclusion criteria. Section 2. Texture feature definition. Figure S1. Data preparation and demographics of all cohorts. Figure S2. Kaplan–Meier curves of patients stratified by MPIS in the subgroup of patients with TNM stage I LUAD in the (a) discovery set; (b) external validation set V1; (c) external validation set V2; (d) external validation set V3. Figure S3. Kaplan–Meier curves of patients stratified by MPIS in the subgroup of patients with early-stage LUAD in the (a) discovery set; (b) external validation set V1; (c) external validation set V2; (d) external validation set V3. Figure S4. Kaplan–Meier curves of patients stratified by MPIS in the subgroups: (a) patients with age &lt; 65 years in the discovery set; (b) patients with age ≥ 65 years in the discovery set; (c) patients with age &lt; 65 years in the external validation set V1; (d) patients with age ≥ 65 years in the external validation set V1; (e) patients with age &lt; 65 years in the external validation set V2; (f) patients with age ≥ 65 years in the external validation set V2; (g) patients with age &lt; 65 years in the external validation set V3; (h) patients with age ≥ 65 years in the external validation set V3. Figure S5. Kaplan–Meier curves of patients stratified by MPIS in the subgroups: (a) male sex in the discovery set; (b) female sex in the discovery set; (c) male sex in the external validation set V1; (d) female sex in the external validation set V1; (e) male sex in the external validation set V2; (f) female sex in the external validation set V2; (g) male sex in the external validation set V3; (h) female sex in the external validation set V3. Figure S6. Kaplan–Meier curves of patients stratified by MPIS in the subgroups: (a) non-smoker in the discovery set; (b) smoker in the discovery set; (c) non-smoker in the external validation set V1; (d) smoker in the external validation set V1; (e) non-smoker in the external validation set V2; (f) smoker in the external validation set V2; (g) non-smoker in the external validation set V3; (h) smoker in the external validation set V3. Figure S7. Kaplan–Meier curves of patients stratified by MPIS in the subgroups: (a) patients without adjuvant chemotherapy in the discovery set; (b) patients received adjuvant chemotherapy in the discovery set; (c) patients without adjuvant chemotherapy in the external validation set V1; (d) patients received adjuvant chemotherapy in the external validation set V1; (e) patients without adjuvant chemotherapy in the external validation set V2; (f) patients received adjuvant chemotherapy in the external validation set V2; (g) patients without adjuvant chemotherapy in the external validation set V3; (h) patients received adjuvant chemotherapy in the external validation set V3. Figure S8. Kaplan–Meier curves of patients stratified by MPIS in the subgroups: (a) patients with well-moderately differentiated cancer in the discovery set; (b) patients with poorly-undifferentiated cancer in the discovery set; (c) patients with well-moderately differentiated cancer in the external validation set V1; (d) patients with poorly-undifferentiated cancer in the external validation set V1; (e) patients with well-moderately differentiated cancer in the external validation set V2; (f) patients with poorly-undifferentiated cancer in the external validation set V2. Figure S9. The visualization of the full model (a) and clinical model (b) as nomograms for patients with resectable LUAD. Figure S10. Kaplan–Meier curves of patients stratified by single-scale pathology image signature at 2.5 × magnification in the (a) discovery set, (b) external validation set V1, (c) external validation set V2, and (d) external validation set V3. Figure S11. Kaplan–Meier curves of patients stratified by single-scale pathology image signature at 10 × magnification in the (a) discovery set, (b) external validation set V1, (c) external validation set V2, and (d) external validation set V3. Figure S12. Kaplan–Meier curves of patients stratified by single-scale pathology image signature at 40 × magnification in the (a) discovery set, (b) external validation set V1, (c) external validation set V2, and (d) external validation set V3. Figure S13. Time-dependent ROC curves and AUC curves of models in the (a) discovery set, (b) external validation set V1, (c) external validation set V2, and (d) external validation set V3. Time-dependent ROC curves are evaluated for 5-year OS (or for 3-year OS), and time-dependent AUC curves are plotted for 12 to 60 months (or 12 to 36 months). Figure S14. Significantly enriched biological pathways in Gene Ontology (GO) enrichment analysis. Table S1. The specific definitions of the selected texture features. Table S2. The LASSO Cox selected features and corresponding coefficients to construct the MPIS. Table S3. The LASSO Cox selected features and corresponding coefficients to construct the single-scale pathology image signature at 2.5 × magnification. Table S4. The LASSO Cox selected features and corresponding coefficients to construct the single-scale pathology image signature at 10 × magnification. Table S5. The LASSO Cox selected features and corresponding coefficients to construct the single-scale pathology image signature at 40 × magnification.